Medtronic receives USFDA approval for InterStim X system to manage bladder and bowel control
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Subscribe To Our Newsletter & Stay Updated